BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 22025173)

  • 1. C-reactive protein as a biomarker for urological cancers.
    Saito K; Kihara K
    Nat Rev Urol; 2011 Oct; 8(12):659-66. PubMed ID: 22025173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of C-reactive protein in urological cancers: a useful biomarker for predicting outcomes.
    Saito K; Kihara K
    Int J Urol; 2013 Feb; 20(2):161-71. PubMed ID: 22897628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Role of C-Reactive Protein In Urological Cancers: A Meta-Analysis.
    Zhou L; Cai X; Liu Q; Jian ZY; Li H; Wang KJ
    Sci Rep; 2015 Aug; 5():12733. PubMed ID: 26235332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of C-reactive protein in urological cancers: a systematic review and meta-analysis.
    Dai J; Tang K; Xiao W; Yu G; Zeng J; Li W; Zhang YQ; Xu H; Chen ZQ; Ye ZQ
    Asian Pac J Cancer Prev; 2014; 15(8):3369-75. PubMed ID: 24870724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C-reactive protein in urologic cancers.
    Huang J; Baum Y; Alemozaffar M; Ogan K; Harris W; Kucuk O; Master VA
    Mol Aspects Med; 2015 Nov; 45():28-36. PubMed ID: 25936279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Author's reply: CRP kinetics could be prognostic predictors in urothelial cancer.
    Saito K; Kihara K
    Nat Rev Urol; 2013 Mar; 10(3):182. PubMed ID: 23381595
    [No Abstract]   [Full Text] [Related]  

  • 7. Role of C-reactive protein as a biomarker for renal cell carcinoma.
    Saito K; Kihara K
    Expert Rev Anticancer Ther; 2010 Dec; 10(12):1979-89. PubMed ID: 21110763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C-reactive protein in bladder cancer: where do we stand?
    Gakis G; Stenzl A
    Nat Rev Urol; 2013 Mar; 10(3):182. PubMed ID: 23381597
    [No Abstract]   [Full Text] [Related]  

  • 9. Biomarker development in the context of urologic cancers.
    Kelloff GJ; Sigman CC; Scher HI
    Urol Oncol; 2015 Jun; 33(6):295-301. PubMed ID: 25746942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Utility of the serum CRP value for assessing the prognosis and therapeutic response of urological malignancies].
    Köhler A; Eggers H; Kuczyk MA; Schrader AJ; Steffens S
    Aktuelle Urol; 2013 Nov; 44(6):452-5. PubMed ID: 24258396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C-reactive protein: a biomarker of survival in patients with localized upper tract urothelial carcinoma treated with radical nephroureterectomy.
    Obata J; Kikuchi E; Tanaka N; Matsumoto K; Hayakawa N; Ide H; Miyajima A; Nakagawa K; Oya M
    Urol Oncol; 2013 Nov; 31(8):1725-30. PubMed ID: 23141922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [MicroRNAs as potential noninvasive markers in the diagnosis of urological malignancies].
    Gilyazova IR; Klimentova EA; Pavlov VN; Khusnutdinova EK
    Urologiia; 2016 Apr; (2):96-102. PubMed ID: 28247670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pooled Analysis of C-Reactive Protein Levels and Mortality in Prostate Cancer Patients.
    Graff JN; Beer TM; Liu B; Sonpavde G; Taioli E
    Clin Genitourin Cancer; 2015 Aug; 13(4):e217-e221. PubMed ID: 25735198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of systemic inflammatory response markers in urological malignancy.
    Ohno Y
    Int J Urol; 2019 Jan; 26(1):31-47. PubMed ID: 30253448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of Markers of Systemic Inflammation for Predicting Survival and Chemotherapeutic Outcomes and Monitoring Tumor Progression in Patients with Unresectable Metastatic Colorectal Cancer.
    Shibutani M; Maeda K; Nagahara H; Ohtani H; Sakurai K; Yamazoe A; Kimura K; Toyokawa T; Amano R; Kubo N; Tanaka H; Muguruma K; Ohira M; Hirakawa K
    Anticancer Res; 2015 Sep; 35(9):5037-46. PubMed ID: 26254405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Progress of Epigenetic Biomarkers in Urological Cancer.
    Wu P; Cao Z; Wu S
    Dis Markers; 2016; 2016():9864047. PubMed ID: 27594736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-coding RNAs as biomarkers in liquid biopsies with a special emphasis on extracellular vesicles in urological malignancies.
    Zeuschner P; Linxweiler J; Junker K
    Expert Rev Mol Diagn; 2020 Feb; 20(2):151-167. PubMed ID: 31499007
    [No Abstract]   [Full Text] [Related]  

  • 18. Epigenetic biomarkers in urological tumors: A systematic review.
    Jerónimo C; Henrique R
    Cancer Lett; 2014 Jan; 342(2):264-74. PubMed ID: 22198482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter prospective study validating the efficacy of a quantitative assessment tool for frailty in patients with urological cancers.
    Soma O; Hatakeyama S; Okamoto T; Fujita N; Hamano I; Tanaka T; Momota M; Yoneyama T; Yamamoto H; Imai A; Yoneyama T; Hashimoto Y; Yoshikawa K; Kawaguchi T; Saitoh H; Nakaji S; Suzuki T; Ohyama C
    Med Oncol; 2019 Sep; 36(10):88. PubMed ID: 31520152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High preoperative C-reactive protein values predict poor survival in patients on chronic hemodialysis undergoing nephrectomy for renal cancer.
    Omae K; Kondo T; Tanabe K
    Urol Oncol; 2015 Feb; 33(2):67.e9-13. PubMed ID: 25130069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.